Brian Pepin is the CEO and founder of Rune Labs. Brian holds an MSEE in electrical engineering from UC Berkeley and a BSEE from the University of Washington. Prior to starting Rune, Brian spent nearly five years at Verily Life Sciences.
Top 3 Takeaways
- It makes sense to use neuromodulation therapies for neurological and psychiatric disorders that inherently fluctuate over time.
- Neuromodulation data is siloed and that slows down research and translation.
- Closed-loop DBS can enable novel, more efficacious therapies.
- [0:47] Brian’s background.
- [1:50] The Google phase.
- [3:10] Brian’s transition into Rune Labs.
- [3:30] Rune in a nutshell.
- [4:32] Unmet needs for brain diseases.
- [5:58] Why neuromodulation instead of drugs.
- [7:30] Need for adaptive therapies.
- [8:53] Impact of neuromodulation in Parkinson’s Disorder.
- [10:54] Who fits the bill for DBS.
- [13:30] Siloed data in neuromodulation.
- [15:15] Competition in DBS.
- [16:45] Initial application of closed-loop DBS is auto-tune.
- [17:30] Closed-loop can enable therapies.
- [19:03] Software development in DBS devices.
- [20:10] Partnerships between medical device companies and AI companies.
- [21:27] Long-term vision for Rune.